Daily ReportOct 13, 2026
Sepsis, October 13 edition
We read 50 papers and selected 3.
Summary
Today’s most impactful sepsis research includes a large phase 3 randomized trial showing that the ExPEC9V vaccine did not prevent invasive Escherichia coli disease despite strong antibody responses, an AI-enabled smartphone ECG tool demonstrating high accuracy for screening sepsis-associated left ventricular dysfunction, and a pilot randomized trial finding that hemoadsorption did not significantly reduce mortality in sepsis-associated persistent severe acute kidney injury. Together, these studies emphasize the importance of definitive clinical validation, biomarker-guided treatment selection, and clinically meaningful endpoints.
Research Themes
- Definitive randomized evaluation of sepsis prevention strategies
- Accessible artificial intelligence diagnostics for hemodynamic risk stratification
- Biomarker-guided extracorporeal therapy and clinically meaningful outcomes
Selected Articles
1. Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).
In this multinational phase 3 trial of 17,701 older adults, ExPEC9V produced robust and sustained antibody responses but did not prevent invasive disease caused by vaccine-targeted ExPEC O-serotypes. Vaccine efficacy was 14.63% with a 95% confidence interval from -106.57% to 65.38%, leading to early discontinuation after a prespecified futility analysis.
Impact: This is a large, rigorously conducted, globally representative phase 3 trial that provides a clinically decisive negative result. It demonstrates that immunogenicity alone did not translate into protection against invasive ExPEC disease and directly informs future vaccine design and trial strategy.
Clinical Implications: ExPEC9V should not be used for prevention of invasive ExPEC disease because efficacy was not demonstrated, and its development was discontinued. Prevention must continue to rely on established urinary-tract infection prevention, early diagnosis, antimicrobial stewardship, and management of underlying risk factors while alternative vaccine strategies are evaluated.
Key Findings
- 17,701 participants were vaccinated: 8,858 received ExPEC9V and 8,843 received placebo.
- There were 24 vaccine-serotype invasive ExPEC disease cases: 11 in the vaccine group and 13 in the placebo group.
- Vaccine efficacy was 14.63% with a 95% confidence interval of -106.57% to 65.38%, indicating no demonstrated protective effect.
- The vaccine generated robust and sustained antibody responses but did not prevent invasive disease.
Methodological Strengths
- Large phase 3 randomized, double-blind, placebo-controlled design conducted at 332 sites in 20 countries.
- Prespecified futility analysis, masked outcome assessment, and ClinicalTrials.gov registration strengthened validity and transparency.
Limitations
- The study enrolled stable adults aged 60 years or older with a recent history of urinary tract infection, so findings may not generalize to younger adults or populations without this risk profile.
- The low number of invasive disease events produced wide confidence intervals and limited precision for estimating vaccine efficacy.
Future Directions: Future vaccine studies should investigate whether protection requires broader antigenic coverage, alternative antigen targets, improved correlates of protection, or selection of populations with higher baseline risk. Trial designs should incorporate clinically relevant invasive disease endpoints rather than relying primarily on immunogenicity.
BACKGROUND: Invasive Escherichia coli disease (IED) caused by extraintestinal pathogenic E. coli (ExPEC) can lead to bacteraemia and sepsis. ExPEC9V is a conjugate vaccine targeting nine E coli O-serotypes that account for most E coli bloodstream infections. We aimed to evaluate ExPEC9V for safety, immunogenicity, and prevention of IED caused by ExPEC9V O-serotypes in adults aged 60 years and older. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study conducted at 332 clinical sites in 20 countries (E.mbrace), we enrolled participants aged 60 years and older in stable health and with a history of urinary tract infection (UTI) within the previous 2 years. Participants were randomly assigned
2. Screening for Left Ventricular Dysfunction in Sepsis Using a Smartphone ECG Analysis Application: A Multicenter Validation Study.
In 425 adults with sepsis from three university hospitals, an artificial intelligence smartphone application analyzing photographed 12-lead ECGs detected left ventricular ejection fraction of 40% or less with an ROC-AUC of 0.901. At the optimized threshold, sensitivity was 89.6%, specificity was 75.1%, and the negative predictive value was 97.5%; performance exceeded NT-proBNP in the available comparison cohort.
Impact: This study translates an artificial intelligence diagnostic approach into a readily deployable smartphone workflow that could support early hemodynamic assessment where echocardiography is delayed or unavailable. Its high negative predictive value is particularly relevant to avoiding excessive fluid administration in sepsis.
Clinical Implications: The application may help identify patients unlikely to have significant left ventricular dysfunction and support cautious fluid and vasopressor decisions. It should be considered a screening adjunct rather than a replacement for echocardiography until prospective, real-time implementation studies confirm clinical benefit and safety.
Key Findings
- The study included 425 adult sepsis patients from three university hospitals.
- The smartphone-derived quantitative ECG score achieved an ROC-AUC of 0.901 for detecting left ventricular ejection fraction of 40% or less.
- At the optimized threshold, sensitivity was 89.6%, specificity was 75.1%, and negative predictive value was 97.5%.
- In the NT-proBNP comparison subset, the smartphone ECG score had a higher ROC-AUC than NT-proBNP: 0.911 versus 0.637.
Methodological Strengths
- Multicenter validation across three university hospitals with paired 12-lead ECG and transthoracic echocardiography.
- The study used a clinically relevant reference standard and prespecified comparison with NT-proBNP.
Limitations
- The retrospective design and requirement for ECG and echocardiography within 72 hours may introduce selection and timing biases.
- The study assessed diagnostic performance rather than whether app-guided management improves fluid balance, organ failure, or mortality.
- The optimal threshold may require recalibration across devices, populations, and care settings.
Future Directions: Prospective studies should test real-time use at emergency department arrival, evaluate integration with echocardiography and perfusion markers, assess performance across different smartphone and ECG systems, and determine whether app-guided management improves patient-centered outcomes.
BACKGROUND: Sepsis-induced left ventricular (LV) dysfunction complicates fluid resuscitation, increasing the risk of pulmonary edema and worsening outcomes. Echocardiographic assessment is often delayed, and natriuretic peptides such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) have limited diagnostic accuracy in this setting. We evaluated a smartphone-based electrocardiogram (ECG) analysis application for screening LV dysfunction in patients with sepsis. METHODS: In this multicenter retrospective observational study, we included 425 adult sepsis patients from three university hospitals who underwent both a 12-lead ECG and transthoracic echocardiography within 72 hours of emergency department admission. ECG images displayed on a monitor were photographed and analyzed using an artificial intelligence (AI)-based smartphone application
3. The effects of hemoadsorption in patients with sepsis-associated persistent severe AKI who require CRRT: A prospective, randomized controlled pilot study.
In this prospective randomized pilot trial of 76 patients with sepsis-associated persistent severe acute kidney injury requiring continuous renal replacement therapy, adding hemoadsorption to continuous venovenous hemofiltration did not significantly reduce 30-day mortality. Mortality was 36.8% with combination therapy versus 52.6% with conventional therapy, but the difference was not statistically significant; a post hoc signal suggested possible benefit in patients with urinary CCL14 levels above 1.3 ng/mL.
Impact: This study provides a clinically important negative result for a widely proposed extracorporeal immunomodulatory strategy. It also generates a testable biomarker-guided hypothesis without overstating the exploratory subgroup finding, thereby helping refine future precision trials.
Clinical Implications: Routine addition of hemoadsorption to continuous venovenous hemofiltration cannot be recommended to reduce mortality in this population based on the available evidence. Urinary CCL14 may help identify a subgroup for future trials, but post hoc findings should not yet guide routine treatment selection.
Key Findings
- Seventy-six patients were randomized equally to continuous venovenous hemofiltration plus hemoadsorption or conventional continuous venovenous hemofiltration.
- Thirty-day mortality was 36.8% in the hemoadsorption group and 52.6% in the control group, without statistical significance.
- Hemoadsorption significantly improved APACHE II and SOFA scores, cytokine clearance, and hemodynamic parameters, but did not improve renal functional prognosis or reduce treatment durations.
- A post hoc exploratory analysis suggested lower mortality with hemoadsorption among patients with urinary CCL14 above 1.3 ng/mL.
Methodological Strengths
- Prospective randomized controlled design with a clinically relevant 30-day mortality endpoint.
- The investigators reported both clinical outcomes and mechanistic treatment-response measures, including cytokine clearance and hemodynamic changes.
Limitations
- The single-center pilot design and small sample size limited statistical power to detect mortality differences.
- The biomarker-defined subgroup finding was post hoc and exploratory, so it may reflect chance and requires prospective confirmation.
- The study did not demonstrate improvement in renal recovery, duration of organ support, intensive care unit stay, or hospital stay.
Future Directions: Future studies should be adequately powered, multicenter, and prospectively stratified by urinary CCL14 or other biologically validated markers. They should prespecify mortality and organ-recovery endpoints, standardize hemoadsorption exposure, and evaluate cost, complications, and timing of treatment.
BACKGROUND: Sepsis-associated persistent severe acute kidney injury (S-PAKI) is marked by a sustained hyperinflammatory response and is associated with a poor prognosis. Hemoadsorption functions by removing circulating cytokines and other inflammatory mediators. This study aims to evaluate the impact of CVVH combined with hemoadsorption on the prognosis of patients with S-PAKI who need CRRT. METHODS: This prospective, randomized, single-center pilot study involved 76 S-PAKI patients who required CRRT. Participants were randomly assigned to receive either CVVH combined with hemoadsorption (CVVH + HA group, n = 38) or conventional CVVH therapy (CVVH group, n = 38). The primary endpoint was 30-day all-cause mortality. Secondary endpoints included changes in Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, renal functional prognosis, alterations in biomarker and cytokine levels, changes in hemodynamic parameters, as well as the duration of renal replacement therapy, mechanical ventilation, ICU stay, and overall hospital stay among survivors.